Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients

2008761 citationsReview

Authors

S. Nalluri · Stony Brook University Hospital

Abstract

The use of bevacizumab was significantly associated with an increased risk of developing venous thromboembolism in cancer patients receiving this drug.

Topics & Keywords

Venous Thromboembolism Diagnosis and Management Cancer Treatment and Pharmacology Vascular Tumors and Angiosarcomas

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA

Volume 300, Issue 19, pp. 2277-2277

DOI: 10.1001/jama.2008.656

Field-Weighted Citation Impact: 32.50